Increased risk of death with melphalan flufenamide.

The US FDA has alerted healthcare professionals and patients about an apparently increased risk of death with melphalan flufenamide [Pepaxto] in patients with multiple myeloma. FDA alerts patients and health care professionals about clinical trial results showing an increased risk of death associated with Pepaxto (melphalan flufenamide). In the OCEAN study, a post-approval requirement, melphalan flufenamide and dexamethasone were compared with pomalidomide and dexamethasone in patients with resistant disease. [Extracted from the article]